IP Library Granted Patent US 7,488,706
Granted Patent B2
US 7,488,706 · App. 11/534,990 · Granted Feb 10, 2009

Alkylamine as an antimicrobial agent in ophthalmic compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,488,706
App. No.
11/534,990
Granted
Feb 10, 2009
Kind
B2
Abstract

A multi-purpose contact lens care solution having high activity against fungi and certain bacteria comprising, in liquid aqueous medium, an alkylamine having the following formula, where R1 is a C 13-17 alkyl, and R2 and R3 are each independently H or —CH 3 , and a non-ionic surfactant. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses in ocular tissue membrane integrity during contact lens wear.

Claims (27)

1. A method for maintaining ocular tissue cell membrane integrity during contact lens wear comprising:

contacting the lens with an aqueous solution comprising from about 0.1 to about 10 ppm of a primary, secondary, or tertiary alkylamine having the following formula

where R1 is a C 13-17 alkyl, and R2 and R3 are each independently H or —CH 3 ; and

a non-ionic surfactant in an amount effective to render the alkylamine soluble in the aqueous solution.

2. The method for disinfecting of claim 1 , wherein the alkylamine is selected from the group consisting of myristylamine and cetylamine.

3. The method for disinfecting claim 1 , wherein the non-ionic surfactant is a polyoxypropylene-polyoxyethylene co-block polymer.

4. The method for disinfecting of claim 1 , where in the aqueous solution further comprises a component selected from the group consisting of a second antimicrobial agent, a viscosity inducing agent, a chelating agent, a buffer, taurine and a tonicity component.

5. A method for maintaining ocular tissue cell membrane integrity during contact lens wear comprising contacting a lens positioned in a user's eye with an isotonic aqueous solution comprising:

an aqueous liquid medium;

a first antimicrobial component in an amount effective to disinfect lens contacted with said solution, the antimicrobial component comprising of a primary, secondary, or tertiary alkyl having the following formula

where R1 is a C 13-17 alkylamine, and R2 and R3 are each independently H or —CH 3 ;

taurine in an amount effective to protect ocular tissue cell membranes;

a non-ionic surfactant in an amount effective in cleaning a contact lens contacted with said solution;

a buffer component in an amount effective in maintaining the pH of said solution within a physiologically acceptable range;

a viscosity inducing component selected from the group consisting of cellulosic derivatives and mixtures thereof in the range of about 0.05% to about 5.0% w/v) of the total solution;

a chelating component in an amount less than 0.05% (w/v) of the total solution; and

a tonicity component in an amount effective in providing the desired tonicity to said solution.

6. A process for mitigating ocular tissue insult comprising:

admininstering an aqueous liquid medium to a user's eye, the aqueous liquid medium comprising:

a first antimicrobial component in an amount effective to disinfect a contact lens contacted with said solution, the antimicrobial component comprising; primary, secondary, or tertiary alkylamine having the following formula

where R1 is a C13-17 alkyl, and R2 and R3 are each independently H or —CH3;

taurine in an amount effective to protect ocular tissue cell membranes; and

a non-ionic surfactant in an amount effective in cleaning a contact lens contacted with said solution.

7. The process of claim 6 , wherein the alkylamine is selected from the group consisting of myristylamine and cetylamine.

8. The process of claim 6 , wherein administering step is conducted so that the aqueous liquid medium is temporarily emplaced in the user's eye.

9. The process of claim 6 , wherein administering step is conducted so that the uptake of the aqueous liquid medium into at least one of a soft-contact lens and a rigid gas permeable tens is achieved.

10. The process of claim 6 , wherein the aqueous liquid medium further comprises a second antimicrobial component.

Assignments (4)
CHANGE OF NAME Recorded Sep 25, 2018
From: ABBOTT MEDICAL OPTICS INC.
To: JOHNSON & JOHNSON SURGICAL VISION, INC.
Reel/Frame 047150/0976 →
MERGER Recorded Jul 29, 2009
From: ADVANCED MEDICAL OPTICS, INC.
To: ABBOTT MEDICAL OPTICS INC.
Reel/Frame 023234/0277 →
RELEASE OF SECURITY INTEREST Recorded Feb 27, 2009
From: BANK OF AMERICA, N.A. AS ADMINISTRATIVE AGENT
To: ADVANCED MEDICAL OPTICS, INC.
Reel/Frame 022320/0427 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 29, 2007
From: ADVANCED MEDICAL OPTICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 019501/0069 →